Transforming obesity: The advancement of multi-receptor drugs
CM Kusminski, D Perez-Tilve, TD Müller, RD DiMarchi… - Cell, 2024 - cell.com
For more than a century, physicians have searched for ways to pharmacologically reduce
excess body fat. The tide has finally turned with recent advances in biochemically …
excess body fat. The tide has finally turned with recent advances in biochemically …
Pharmacological advances in incretin-based polyagonism: what we know and what we don't
A Novikoff, TD Müller - Physiology, 2024 - journals.physiology.org
The prevalence of obesity continues to rise in both adolescents and adults, in parallel
obesity is strongly associated with the increased incidence of type 2 diabetes, heart failure …
obesity is strongly associated with the increased incidence of type 2 diabetes, heart failure …
The role of incretin receptor agonists in the treatment of obesity
T Forst, C De Block, S Del Prato… - Diabetes, Obesity …, 2024 - Wiley Online Library
Introdroduction Obesity and its associated metabolic conditions have become a significant
global health problem in recent years, with many people living with obesity fulfilling criteria …
global health problem in recent years, with many people living with obesity fulfilling criteria …
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Introduction Incretin-based therapies have emerged as effective treatments for type 2
diabetes (T2D) and obesity. However, not all patients achieve optimal outcomes with …
diabetes (T2D) and obesity. However, not all patients achieve optimal outcomes with …
Regulation of energy metabolism through central GIPR signaling
A Liskiewicz, TD Müller - Peptides, 2024 - Elsevier
In recent years, significant progress has been made to pharmacologically combat the
obesity pandemic, particularly with regard to biochemically tailored drugs that …
obesity pandemic, particularly with regard to biochemically tailored drugs that …
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network …
Z Xie, G Zheng, Z Liang, M Li, W Deng, W Cao - Metabolism, 2024 - Elsevier
Purpose This study aimed to provide evidence-based support and a reference for the
efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and …
efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and …
Cholecystokinin-expressing neurons of the ventromedial hypothalamic nucleus control energy homeostasis
V Eftychidis, TJ Ellender, J Szymanski… - Frontiers in cellular …, 2024 - frontiersin.org
The hypothalamus is the primary center of the brain that regulates energy homeostasis. The
ventromedial hypothalamus (VMH) plays a central role in maintaining energy balance by …
ventromedial hypothalamus (VMH) plays a central role in maintaining energy balance by …
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
M Nicze, A Dec, M Borówka, D Krzyżak… - International …, 2024 - pmc.ncbi.nlm.nih.gov
Obesity is a chronic disease caused primarily by the imbalance between the amount of
calories supplied to the body and energy expenditure. Not only does it deteriorate the quality …
calories supplied to the body and energy expenditure. Not only does it deteriorate the quality …